Actively Recruiting
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
Led by University of Washington · Updated on 2025-07-28
350
Participants Needed
6
Research Sites
143 weeks
Total Duration
On this page
Sponsors
U
University of Washington
Lead Sponsor
U
University of Alabama at Birmingham
Collaborating Sponsor
AI-Summary
What this Trial Is About
Study Hypothesis/Question In infants born very preterm, advancing enteral feeds after 24 hours from birth (limited trophic feeds) versus after 72 hours (extended trophic feeds) reduces the risk of all-cause late onset sepsis (LOS) without increasing the risk of other adverse outcomes. Study Design Type This is a multi-center, open-label, parallel-group, individual randomized controlled trial comparing two different trophic feeding regimens in preterm infants born between 25w0d and 31w6d. These infants will be randomly assigned to either the intervention group, receiving limited trophic feeding (20 to 25 mL/kg/day for one day) or the control group, receiving extended trophic feeding (20 to 25 mL/kg/day for three days) prior to advancing enteral feeds until full feeding volume (140 mL/kg/day) is achieved. Eligibility Criteria Preterm infants with gestational ages between 25 0/7 and 31 6/7 weeks and a birthweight of \<1500 grams who are admitted to six participating neonatal units will be eligible for inclusion. Infants with \<5th percentile for weight at birth, vasopressor use within first 24 hours of life major congenital/genetic anomalies affecting enteral feeding, growth, or mortality, and those with a terminal illness in which decisions to withhold or limit support have been made will be excluded. Infants of parents or legal guardians who are unable to provide consent within 36 hours of birth will also be excluded. Study Intervention/Methods Written parental informed consent will be obtained prenatally or within the first 36 hours of birth. Infants will be randomized to receive limited trophic feeds of 24 to 36 hours or extended trophic feeds for 72 hours prior to the advancement of enteral feeds. Infants will be fed parent's own milk (POM) with donor human milk as the alternative if POM is unavailable. Primary Outcome Late-onset sepsis, defined as positive blood, urine, and/or cerebrospinal fluid (CSF) cultures in the presence of compatible clinical signs of sepsis, occurring after postnatal day 3 and before hospital discharge, and treated with antibiotics for 5 days or more. Secondary Outcome(s) The trial will assess various secondary outcomes including length of hospital stay, all-cause in-hospital mortality, duration of IV fluids and central line utilization, necrotizing enterocolitis (Bell's stage IIa or higher), severe intraventricular hemorrhage (grade III or IV either unilaterally or bilaterally), bronchopulmonary dysplasia (oxygen requirement or positive pressure ventilation at 36 weeks corrected gestational age), or retinopathy of prematurity requiring intervention. Additionally, growth metrics throughout hospitalization will be evaluated using change in weight, length, and head circumference z-scores from birth to 36 weeks' corrected gestational age between infants in the limited and extended trophic feeding groups.
CONDITIONS
Official Title
Limited Versus Extended Trophic Feeding (LET-FEED) Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Birthweight less than 1500 grams
- Born between 25 weeks 0 days and 31 weeks 6 days gestation
- Consent to feed donor milk if parent's own milk is unavailable or insufficient
You will not qualify if you...
- Birthweight below 5th percentile for age (Fenton growth curve)
- Parent or guardian unable to provide consent within 36 hours after birth
- Major congenital anomalies affecting feeding decisions (e.g., gastroschisis, omphalocele, congenital diaphragmatic hernia, congenital heart disease)
- Known genetic conditions affecting growth, feeding, or survival
- Use of vasopressors (except hydrocortisone) within first 24 hours after birth
- Infant considered terminally ill
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
Not Yet Recruiting
2
University of South Florida
Tampa, Florida, United States, 33606
Not Yet Recruiting
3
University of Oklahoma
Oklahoma City, Oklahoma, United States, 73104
Not Yet Recruiting
4
Baylor College of Medicine
Houston, Texas, United States, 77030
Not Yet Recruiting
5
University of Washington
Seattle, Washington, United States, 98195
Not Yet Recruiting
6
St. Joseph's Medical Center
Tacoma, Washington, United States, 98405
Actively Recruiting
Research Team
G
Gregory C Valentine, MD MED FAAP
CONTACT
A
Ariel Salas, MD, MSPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here